Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR”

2,360 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,360 results

Not applicableLooking for participantsNCT06643000
What this trial is testing

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Who this might be right for
Non-small Cell Lung CancerLeptomeningeal MetastasisEGFR Gene Mutation
Henan Cancer Hospital 60
Early research (Phase 1)Study completedNCT00444015
What this trial is testing

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small-Cell Lung Carcinoma
H. Lee Moffitt Cancer Center and Research Institute 34
Testing effectiveness (Phase 2)UnknownNCT02631460
What this trial is testing

S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

Who this might be right for
NSCLC
Sun Yat-sen University 470
Large-scale testing (Phase 3)UnknownNCT02633189
What this trial is testing

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
National Cancer Institute, Naples 200
Not applicableStudy completedNCT01015326
What this trial is testing

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

Who this might be right for
Skin Toxicities
Northwestern University 32
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Early research (Phase 1)Study completedNCT00551850
What this trial is testing

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Who this might be right for
Advanced CancerRefractory Cancer
AVEO Pharmaceuticals, Inc. 37
Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Not applicableUnknownNCT02666755
What this trial is testing

Novel Detection System for Lung Cancer Curative Effect Monitoring

Who this might be right for
Lung Neoplasms
Jian Zhang 160
Testing effectiveness (Phase 2)Study completedNCT01271725
What this trial is testing

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 74
Early research (Phase 1)Study completedNCT00369252
What this trial is testing

Phase I Study of Nimotuzumab in Solid Tumours

Who this might be right for
Advanced and/or Metastatic Solid Tumours
YM BioSciences 18
Testing effectiveness (Phase 2)Study completedNCT00072631
What this trial is testing

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung CancerFailed Prior Chemotherapy
OSI Pharmaceuticals 43
Testing effectiveness (Phase 2)Study completedNCT03736837
What this trial is testing

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Study completedNCT00922584
What this trial is testing

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Who this might be right for
Non-Small Cell Lung Cancer
Chinese Society of Lung Cancer 65
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06492317
What this trial is testing

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 20
Not applicableLooking for participantsNCT06715839
What this trial is testing

Target-specific immunoPET Imaging of Digestive System Carcinoma

Who this might be right for
MalignancyDigestive CancerDigestive System Neoplasm+12 more
RenJi Hospital 400
Large-scale testing (Phase 3)Study completedNCT02586025
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Who this might be right for
Breast Cancer
Hoffmann-La Roche 329
Testing effectiveness (Phase 2)UnknownNCT04553887
What this trial is testing

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 53
Load More Results